SEC filing record
Primary Source · SEC.gov

Potrero Medical, Inc.

2026 vintageRule 506(c)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-05-29Last filing 2026-05-29

Raised

$7M

Investors

56

Min Invest

$1,318

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Potrero Medical, Inc. is a Delaware corporation that first filed a Form D on May 27, 2014 and most recently amended it on May 29, 2026 in the Biotechnology industry group. The offering claims Rule 506(c) and covers equity. Potrero Medical, Inc. reported $6,500,000 sold from 56 investors of a $6,500,000 total offering as of the Form D filed May 29, 2026. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,318. The Form D names Ceros Financial Services, Inc. (CRD 37869), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $650,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 26142 Eden Landing Rd., Hayward, CA 94545.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001609048
Entity NamePotrero Medical, Inc.
ExemptionRule 506(c)
What the exemption meansRule 506(c) of Regulation D: the issuer may advertise the offering publicly, but every purchaser must be a verified accredited investor.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address26142 Eden Landing Rd., Hayward, CA 94545
Phone(415) 926-8616
Former NamesConsano Medical, Inc. (until May 27, 2014)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateMay 8, 2026
Filing DateMay 29, 2026
Accession Number0001609048-26-000002
Total Offering Amount$6,500,000
Total Amount Sold$6,500,000
Amount Remaining$0
Total Investors56
Non-Accredited InvestorsNone
Minimum Investment$1,318
Offering DurationOne year or less
Sales Commissions$650,000 (to Ceros Financial Services, Inc.)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment Count10 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest May 29, 2026

Critical / warning

0 / 0

0 watch · 3 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

7

raising, lapsed, closed

Latest event New filer · May 29, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-05-29, and alerts on the next one
  • 7 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-05-29: 5 related persons added and 2 removed against the filing of 2025-09-02; 10 now listed. The names are in the Terminal feed.

Christopher Dewey

Director · HAYWARD, CA

Mark Goldwasser

Director · HAYWARD, CA

Maurice Ferre

Director · HAYWARD, CA

Ram Reddy

Director · HAYWARD, CA

David Matlin

Director · HAYWARD, CA

Mike Stansky

Director · HAYWARD, CA

Clay Heighten

Director · HAYWARD, CA

Todd Dunn

Executive Officer · HAYWARD, CA

CEO

Khalid Ghafari

Executive Officer · HAYWARD, CA

CFO

Rich Keenan

Executive Officer · HAYWARD, CA

CPO

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Ceros Financial Services, Inc.CRD 37869 on BrokerCheck

Associated broker-dealer: None · Rockville, MD · Soliciting in all states

Questions About Potrero Medical, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Potrero Medical, Inc.?

Potrero Medical, Inc. is a Delaware corporation that filed a Form D with the SEC on May 29, 2026 in the Biotechnology industry group. The filing claims Rule 506(c) for an offering of equity.

Is Potrero Medical, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Potrero Medical, Inc. filed a Form D with the SEC on May 29, 2026 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $6,500,000 sold to 56 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Potrero Medical, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Potrero Medical, Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Potrero Medical, Inc. raised?

Potrero Medical, Inc. reported $6,500,000 sold from 56 investors of a $6,500,000 total offering as of the Form D filed May 29, 2026.

Who can invest in Potrero Medical, Inc.?

The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,318.

What is the minimum investment in Potrero Medical, Inc.?

The Form D lists $1,318 as the minimum investment accepted from any outside investor as of May 29, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Potrero Medical, Inc. and how are they paid?

The Form D names Ceros Financial Services, Inc. (CRD 37869), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $650,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Potrero Medical, Inc.?

The Form D lists 10 related persons: Christopher Dewey, director; Mark Goldwasser, director; Maurice Ferre, director; Ram Reddy, director; David Matlin, director; Mike Stansky, director; Clay Heighten, director; Todd Dunn, executive officer (CEO), and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Potrero Medical, Inc. located?

The issuer's address on its SEC filings is 26142 Eden Landing Rd., Hayward, CA 94545. Its phone number of record is 415-926-8616. It is organized under the laws of Delaware.

How long is the Potrero Medical, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is Potrero Medical, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.